Tagraxofusp-erzs Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: DT(388)-IL3 Fusion Protein, DT388IL3 fusion protein, Diphtheria Toxin(388)-Interleukin-3 Fusion Protein, Elzonris, IL3R-targeting Fusion Protein SL-401, SL 401, SL-401, SL401, Tagraxofusp, Tagraxofusp ERZS

Filter by location:

Duarte, California1 trial

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

City of Hope Medical Center

Phase 1

Houston, Texas1 trial

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.